This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We may also share information about your use of our site with analytics partners. Read about cookies in our Cookie Policy. By clicking “Accept”, you are indicating your consent to our use of cookies and policies.

ANGITIA - INNOVATION FOR PATIENTS

INNOVATION FOR PATIENTS
About us

Founded in 2018, Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the key unmet medical needs in serious musculoskeletal diseases. With our team's experience and scientific expertise in novel drug development, Angitia is dedicated to bringing innovative therapies to help patients in need.

Diseases
Degenerative Disc Disease
Osteoporosis
Osteogenesis Imperfecta
Bone Metastasis
Nonunion
Osteoarthritis
Muscle Disorders
We Focus on
Musculoskeletal Diseases
More information
Careers
Become an Angitian! Angitia is a global company with a diverse team.
Our company culture revolves around respect and equality.
We are committed to fostering employee growth and career development.
More‧‧‧‧‧
Media & News
2024.09.30
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024
2024.09.17
Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024
Abstracts selected for 2 oral presentations and 2 poster presentations, including clinical and preclinical data sets
2024.05.16
Angitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2118
WOODLAND HILLS, California, USA, May 16, 2024 – Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced positive top-line results from its first in human (FIH) study of AGA2118. The study, entitled “A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women”, demonstrates an excellent safety and tolerability profile, as well as preliminary efficacy in increasing bone mineral density (BMD) after single and multiple dose administrations.
more news...